{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:06:11Z","timestamp":1785546371746,"version":"3.56.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.pcad.2016.10.002","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T13:46:50Z","timestamp":1477057610000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?"],"prefix":"10.1016","volume":"59","author":[{"given":"Chirag","family":"Bavishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sripal","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz H.","family":"Messerli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pcad.2016.10.002_bb0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11906-013-0340-9","article-title":"High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs","volume":"15","author":"Bromfield","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.pcad.2016.10.002_bb0010","author":"World Health Organization"},{"issue":"9","key":"10.1016\/j.pcad.2016.10.002_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.18553\/jmcp.2010.16.9.671","article-title":"ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008","volume":"16","author":"Bian","year":"2010","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"10.1016\/j.pcad.2016.10.002_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"issue":"9287","key":"10.1016\/j.pcad.2016.10.002_bb0025","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"Group PC","year":"2001","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pcad.2016.10.002_bb0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","article-title":"The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function","volume":"87","author":"Pitt","year":"2001","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.pcad.2016.10.002_bb0035","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pcad.2016.10.002_bb0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/er.2003-0001","article-title":"Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation","volume":"24","author":"Carey","year":"2003","journal-title":"Endocr Rev"},{"issue":"9230","key":"10.1016\/j.pcad.2016.10.002_bb0045","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9149(99)80791-7","article-title":"Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study","volume":"76","author":"Kober","year":"1995","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2016.10.002_bb0060","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","article-title":"Results of the pilot study for the Hypertension in the Very Elderly Trial","volume":"21","author":"Bulpitt","year":"2003","journal-title":"J Hypertens"},{"issue":"9153","key":"10.1016\/j.pcad.2016.10.002_bb0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.pcad.2016.10.002_bb0070","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"Officers A, Coordinators for the ACRGTA","year":"2002","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.pcad.2016.10.002_bb0075","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"9489","key":"10.1016\/j.pcad.2016.10.002_bb0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"issue":"9590","key":"10.1016\/j.pcad.2016.10.002_bb0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.pcad.2016.10.002_bb0090","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"issue":"12","key":"10.1016\/j.pcad.2016.10.002_bb0100","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.pcad.2016.10.002_bb0105","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"Group NS","year":"2010","journal-title":"N Engl J Med"},{"issue":"9311","key":"10.1016\/j.pcad.2016.10.002_bb0110","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"issue":"9446","key":"10.1016\/j.pcad.2016.10.002_bb0115","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"9426","key":"10.1016\/j.pcad.2016.10.002_bb0120","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.002_bb0125","doi-asserted-by":"crossref","first-page":"d2234","DOI":"10.1136\/bmj.d2234","article-title":"Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials","volume":"342","author":"Bangalore","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.pcad.2016.10.002_bb0130","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/hr.2012.185","article-title":"Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis","volume":"36","author":"Chen","year":"2013","journal-title":"Hypertens Res"},{"issue":"23","key":"10.1016\/j.pcad.2016.10.002_bb0135","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pcad.2016.10.002_bb0140","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pcad.2016.10.002_bb0145","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Nicholls","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0150","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-148-1-200801010-00189","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension","volume":"148","author":"Matchar","year":"2008","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.pcad.2016.10.002_bb0160","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pcad.2016.10.002_bb0165","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators O","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.pcad.2016.10.002_bb0175","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200018080-00020","article-title":"Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients","volume":"18","author":"Azizi","year":"2000","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.pcad.2016.10.002_bb0180","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1524-6175.2004.03511.x","article-title":"Amaze. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials","volume":"6","author":"Izzo","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0185","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"issue":"18","key":"10.1016\/j.pcad.2016.10.002_bb0190","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/eurheartj\/ehq255","article-title":"Of fads, fashion, surrogate endpoints and dual RAS blockade","volume":"31","author":"Messerli","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.10.002_bb0195","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"issue":"9638","key":"10.1016\/j.pcad.2016.10.002_bb0200","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/HYPERTENSIONAHA.114.03903","article-title":"Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis","volume":"64","author":"Diaz","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2016.10.002_bb0210","doi-asserted-by":"crossref","first-page":"i4098","DOI":"10.1136\/bmj.i4098","article-title":"Blood pressure variability and cardiovascular disease: systematic review and meta-analysis","volume":"354","author":"Stevens","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pcad.2016.10.002_bb0215","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/HYPERTENSIONAHA.112.194340","article-title":"Short- and long-term blood pressure variability: present and future","volume":"60","author":"Mancia","year":"2012","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0220","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jash.2014.02.004","article-title":"Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials","volume":"8","author":"Wang","year":"2014","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"10.1016\/j.pcad.2016.10.002_bb0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/HYPERTENSIONAHA.111.174383","article-title":"Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study","volume":"58","author":"Zhang","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2016.10.002_bb0230","author":"American Diabetes Association"},{"issue":"Suppl. 1","key":"10.1016\/j.pcad.2016.10.002_bb0235","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes \u2013 2014","volume":"37","author":"American Diabetes A","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.pcad.2016.10.002_bb0240","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M15-3016","article-title":"Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes","volume":"164","author":"Chamberlain","year":"2016","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","article-title":"Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"32","author":"Weber","year":"2014","journal-title":"J Hypertens"},{"issue":"Suppl. 2","key":"10.1016\/j.pcad.2016.10.002_bb0250","doi-asserted-by":"crossref","first-page":"S320","DOI":"10.2337\/dc11-s248","article-title":"RAS blockade for every diabetic patient: pro and con","volume":"34","author":"Ruilope","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2016.10.002_bb0255","doi-asserted-by":"crossref","first-page":"i438","DOI":"10.1136\/bmj.i438","article-title":"Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials","volume":"352","author":"Bangalore","year":"2016","journal-title":"BMJ"},{"issue":"9502","key":"10.1016\/j.pcad.2016.10.002_bb0260","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","article-title":"Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis","volume":"366","author":"Casas","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pcad.2016.10.002_bb0265","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"28","key":"10.1016\/j.pcad.2016.10.002_bb0270","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pcad.2016.10.002_bb0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0285","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.pcad.2016.10.002_bb0290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.pcad.2016.10.002_bb0295","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting\u2013enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"issue":"9192","key":"10.1016\/j.pcad.2016.10.002_bb0300","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.10.002_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjcard.2016.07.074","article-title":"Meta-analysis of randomized trials on the efficacy and safety of angiotensin-converting enzyme inhibitors in patients \u226565 years of age","author":"Bavishi","year":"2016","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.pcad.2016.10.002_bb0310","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0735-1097(01)01161-5","article-title":"Are all angiotensin-converting enzyme inhibitors interchangeable?","volume":"37","author":"Furberg","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2016.10.002_bb0315","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.pcad.2016.10.002_bb0320","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","article-title":"Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials","volume":"36","author":"Bavishi","year":"2015","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.pcad.2016.10.002_bb0325","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehr253","article-title":"Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches","volume":"32","author":"Unger","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016301116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016301116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T19:28:27Z","timestamp":1657481307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016301116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0033062016301116"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.10.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}